Speakers
Faheem Ahmed, M.D.
Investment Advisor
Metaphys
Steve Bates
Executive Chair, The Office for Life Sciences (OLS) & CEO
BIA (U.K. BioIndustry Association)
Kate Bingham
Managing Partner
SV Health Investors
David Bredt, M.D., Ph.D.
Founder, Chief Scientific Officer
Rapport Therapeutics
Peter Campbell, Ph.D.
Academic Co-Founder & Chief Scientific Officer
Quotient Therapeutics
Jacques Carolan, Ph.D.
Programme Director
ARIA
Sarah Cole, Ph.D.
CEO
SENISCA Ltd.
Miles Congreve, Ph.D.
Chief Scientific Officer
Isomorphic Labs
Lee Cronin
CEO, Chemify and Regius Professor of Chemistry
University of Glasgow
Kevin Eggan
Chief Scientific Officer
Biomarin
Simone Fishburn, Ph.D.
VP & Editor in Chief
BioCentury Inc.
Tim Funnell
Partner
Monograph Capital
Shaun Grady
Chair, U.K.
AstraZeneca
Anika Gupta, Ph.D.
Principal
GV
Stephen Hansen
Director of Biopharma Intelligence
BioCentury Inc.
Masato Hata, Ph.D.
Deputy Head of Research Institute Munich, Oncology Lead
Daiichi Sankyo Europe
Rob Hershberg, M.D., Ph.D.
Venture Partner
Frazier Life Sciences
Susan Hill, Ph.D.
CEO
Mestag Therapeutics
Chris Hollowood, Ph.D.
CEO
Syncona
Anne Horgan, Ph.D.
Partner
Cambridge Innovation Capital (CIC)
Steve Jackson, Ph.D.
Professor of Biology, Cambridge and Group Leader
Cancer Research UK
Annalisa Jenkins, MBBS FRCP
Non-Executive Director
LetterOne
Michelle Jones, Ph.D.
Chief Operating Officer
Astex Therapeutics
Selina Koch, Ph.D.
Executive Editor, Head of Intelligence & Research
BioCentury Inc.
Susanne Kreutz, Ph.D.
Global Head of Corporate & Business Development
Novartis
Laura Lane, Ph.D.
VP, Lilly Ventures & European Head
Eli Lilly and Co.
Alex Leech
Partner
Sofinnova Partners
John Lepore, M.D.
President and CEO
ProFound Therapeutics
Jing Liang, Ph.D.
Managing Partner
Umbrex
Husseini Manji, M.D.
Professor, Oxford University & Visiting Professor, Duke University and Co-chair,
UK Govt Mental Health Mission
Marianne Mertens, Ph.D.
Partner
Apollo Health Ventures
Andrew Miles
Chief Business Officer
Our Future Health UK
Paul Nioi, Ph.D.
SVP, Research
Alnylam Pharmaceuticals
Stephen O'Rahilly
Professor of Clinical Biochemistry and Medicine
University of Cambridge
Jane Osbourn, Ph.D.
CEO
Alchemab Therapeutics Ltd.
Slavé Petrovski, Ph.D.
VP, Centre for Genomics Research
AstraZeneca
Adam Platt, Ph.D.
VP of Translational Science and Experimental Medicine
AstraZeneca
Koustubh Ranade, Ph.D.
SVP and Head of Translational Medicine
Immunocore
Kiran Reddy, M.D.
Senior Managing Director
Blackstone
Martin Rutter, M.D.
Deputy Chief Scientist
UK Biobank
Kristin-Anne Rutter
Executive Director
Cambridge University Health Partners (CUHP)
James Sabry, M.D., Ph.D.
EVP & Chief Business Officer
BioMarin
Valentina Sartori
Partner
McKinsey & Company
Nadeem Sarwar, Ph.D.
Co-Founder and Head, Transformational Prevention Unit
Novo Nordisk
Robert Scott, Ph.D.
VP Human Genetics
GSK
Otello Stampacchia, Ph.D.
Founder and Managing Director
Omega Funds
Paul Peter Tak, M.D., Ph.D.
President and CEO
Candel Therapeutics
Victoria Taylor
Associate
Medicxi
Sarah Teichmann
Professor and Chair
Cambridge Stem Cell Institute
Morgan Thelander
Chief Operating Officer
J.Thelander Consulting
Jody Thelander
Founder & CEO
J.Thelander Consulting
Richard Tillyer, Ph.D.
Global Head, Discovery, Product Development and Supply
Johnson & Johnson Innovative Medicine
Karen Tkach Tuzman, Ph.D.
Director of Biopharma Intelligence and Head of Discovery and Preclinical Research
BioCentury Inc.
Patrick Vallance, KCB
Minister of State for Science, Research and Innovation
Department for Science, Innovation and Technology
Jérôme Van Biervliet, Ph.D.
Managing Director
VIB
Jean-Philippe Vert, Ph.D.
CEO
Bioptimus
Alice Vickers, Ph.D.
Biotech Investment Associate
Forbion
Annelise Vuidepot, Ph.D.
SVP, CTO, Research and UK Site Lead
Immunocore Holdings plc
Bo Wang, Ph.D.
SVP and Head of Biomedical AI
Xaira
Douglas Williams, Ph.D.
CEO
TriArm Therapeutics